Treatment of Diabetic Foot Infections: A Prospective Study Highlighting the Efficacy and Safety of Moxifloxacin

Bikha Ram Devrajani, Samar Raza, Rubina Khushik, Syed Zulfiquar Ali Shah, Sanam Mari, Sindhu Laghari, Neeta Maheshwary

Abstract


Background: Foot infection involving the skin, soft tissues and bony structures, is a common complication of foot ulcers in diabetic individuals and represents a major cause of morbidity and mortality. Systemic antibiotic treatment must be given as early as possible initially on empirical basis and based on the response to empirical therapy and wound culture and sensitivity results, definitive therapy should be decided. This study was conducted to assess the efficacy and safety of moxifloxacin for treating diabetic foot infections in Pakistani population.

Methods: After taking ethical approval, an interventional phase IV study was conducted in the department of medicine and diabetic clinic, Liaquat University Hospital, Jamshoro, Hyderabad from March 2017 till August 2017. A total of 75 patients with diabetic foot infection who were sensitive to moxifloxacin on culture and sensitivity were included in the study using non-probability convenient sampling technique. All the demographic and clinical information was collected by using a questionnaire specially designed for the study. After making clinical assessment, all the patients were treated with sequential intravenous/oral moxifloxacin for 14 days. Bacteriologic response was based on the results of cultures of specimens of infected skin or soft tissue or blood. The data were analyzed on SPSS version 20.0. Chi-square test was used with significant level set at 0.05.

Results: The study results revealed that the majority of patients with diabetic foot ulcer were males with the age of greater than 45 years. Only 21.3% of them had a comorbidity, either hypertension alone or hypertension with ischemic heart disease, whereas 84% of them reported their foot ulcers to be cured at the end of treatment. Furthermore, only younger age was found to have a significant positive association with healing of foot ulcers.

Conclusions: Moxifloxacin is effective in treating diabetic foot infections and 84% of the diabetic patients in the present study reported the healing of foot ulcers as a result of a 2-week moxifloxacin treatment. Further evaluation of the role of moxifloxacin in the treatment of diabetic foot ulcer is recommended.




J Endocrinol Metab. 2018;8(2-3):32-36
doi: https://doi.org/10.14740/jem485w


Keywords


Clinical trial; Safety and efficacy; Moxifloxacin; Diabetic foot infections

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!